Amit Patel, MD
Advanced Heart Failure and Transplant Cardiology · Indianapolis, INNPI 1710205984
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 52.1% of the total. 2025 is the largest year on record at $24,966, more than ten times the $216 reported in 2019.
Across 70 payments — averaging $585.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$21K
- Bayer$15K
- Abbott$3K
- Abiomed$613
- Impulse Dynamics (USA) Inc.$286
- Medtronic$144
- plus $634 from 8 others
Across 58 payments — averaging $3409.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$130K
- Baxter Healthcare$41K
- Akcea Therapeutics, Inc.$28K
What the payments were for
- Consulting fees$8,46021%
- Speaking & faculty fees$22,73755%
- Travel & lodging$5,09012%
- Food & beverage$4,70911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 21 | $21,349 |
| Bayer | 8 | $14,984 |
| Abbott | 24 | $2,985 |
| Abiomed | 4 | $613 |
| Impulse Dynamics (USA) Inc. | 2 | $286 |
| Medtronic | 1 | $144 |
| Boston Scientific | 1 | $139 |
| Novo Nordisk | 1 | $116 |
| AstraZeneca | 1 | $114 |
| Edwards Lifesciences | 2 | $109 |
| Pfizer | 1 | $84 |
| Cvrx, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$14,984
- AMVUTTRA$9,450
- ONPATTRO$7,500
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,280
- Impella$613
- OPTIMIZER$573
- Simulus$144
- CARDIOMEMS$140
- VIGILANT X4 CRT-D$139
How this compares
$40,996 in reported general payments places this provider in the 70th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
See all advanced heart failure and transplant cardiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 188 | $4,477,553 |
| VyndaqelTafamidis Meglumine | 63 | $1,503,380 |
| OnpattroPatisiran Sodium,lipid Complex | 20 | $554,834 |
| EntrestoSacubitril/Valsartan | 253 | $330,956 |
| JardianceEmpagliflozin | 169 | $236,066 |
| EliquisApixaban | 141 | $173,056 |
| FarxigaDapagliflozin Propanediol | 156 | $164,484 |
| MounjaroTirzepatide | 85 | $101,521 |
| Repatha SureclickEvolocumab | 85 | $100,882 |
| OzempicSemaglutide | 45 | $77,346 |
| KerendiaFinerenone | 30 | $41,128 |
| VascepaIcosapent Ethyl | 68 | $36,276 |
| Tolvaptan | 12 | $28,080 |
| CorlanorIvabradine Hcl | 25 | $15,560 |
| Praluent PenAlirocumab | 13 | $13,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $84 | $6,153,990392 claims |
| Alnylam Pharmaceuticals Inc.Onpattro | $21,349 | $554,83420 claims |
| AstraZenecaFarxiga | $114 | $164,484156 claims |
| Novo NordiskOzempic | $116 | $77,34645 claims |
| BayerKerendia | $14,984 | $41,12830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
Other advanced heart failure and transplant cardiology in Indianapolis
- Sasikanth AdigopulaIndianapolis$310K
- Ashwin RavichandranIndianapolis$284K
- Rafael Garcia-CortesIndianapolis$101K
- Sunit-Preet ChaudhryIndianapolis$27K
- Radha KannegantiIndianapolis$18K
- Mary WalshIndianapolis$17K
- Bhavana Siddegowda-BangaloreIndianapolis$5K
- Sangita SudharshanIndianapolis$2K
- Muhamad SafiiaIndianapolis$2K
- Philip KirlinIndianapolis$967
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.